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ORIGINAL RESEARCH
Sirtuin 1 Mediates Protection Against 
Delayed Cerebral Ischemia in Subarachnoid 
Hemorrhage in Response to Hypoxic 
Postconditioning
Deepti Diwan , PhD*; Ananth K. Vellimana , MD*; Diane J. Aum, MD; Julian Clarke , BS; James W. Nelson, PhD; 
Molly Lawrence, BS; Byung Hee Han, PhD; Jeffrey M. Gidday , PhD; Gregory J. Zipfel , MD
BACKGROUND: Many therapies designed to prevent delayed cerebral ischemia (DCI) and improve neurological outcome in an-
eurysmal subarachnoid hemorrhage (SAH) have failed, likely because of targeting only one element of what has proven to be 
a multifactorial disease. We previously demonstrated that initiating hypoxic conditioning before SAH (hypoxic preconditioning) 
provides powerful protection against DCI. Here, we expanded upon these findings to determine whether hypoxic conditioning 
delivered at clinically relevant time points after SAH (hypoxic postconditioning) provides similarly robust DCI protection.
METHODS AND RESULTS: In this study, we found that hypoxic postconditioning (8% O2 for 2 hours) initiated 3 hours after SAH 
provides strong protection against cerebral vasospasm, microvessel thrombi, and neurological deficits. By pharmacologic 
and genetic inhibition of SIRT1 (sirtuin 1) using EX527 and global Sirt1−/− mice, respectively, we demonstrated that this mul-
tifaceted DCI protection is SIRT1 mediated. Moreover, genetic overexpression of SIRT1 using Sirt1- Tg mice, mimicked the 
DCI protection afforded by hypoxic postconditioning. Finally, we found that post- SAH administration of resveratrol attenuated 
cerebral vasospasm, microvessel thrombi, and neurological deficits, and did so in a SIRT1- dependent fashion.
CONCLUSIONS: The present study indicates that hypoxic postconditioning provides powerful DCI protection when initiated at 
clinically relevant time points, and that pharmacologic augmentation of SIRT1 activity after SAH can mimic this beneficial ef-
fect. We conclude that conditioning- based therapies administered after SAH hold translational promise for patients with SAH 
and warrant further investigation.
Key Words: delayed cerebral ischemia ■ microvessel thrombi ■ postconditioning ■ resveratrol ■ SIRT1 ■ subarachnoid hemorrhage ■ 
vasospasm
Aneurysmal subarachnoid hemorrhage (SAH) is a devastating cerebrovascular disease with sig-nificant morbidity and mortality.1 Despite effec-
tive aneurysm treatment, ≈30% of patients develop 
long- term cognitive and neurological deficits that 
significantly affect their capacity to return to work or 
daily life unassisted.2 Much of this stems from a sec-
ondary ischemic phenomenon referred to as delayed 
cerebral ischemia (DCI), which typically occurs 4 
to 12  days after the initial hemorrhage.3 Though pri-
marily attributed for many years to large- artery vaso-
spasm, DCI is now understood to be a multifactorial 
process driven by additional pathophysiological events 
including microvessel thrombosis,4 microvascular au-
toregulatory dysfunction,5 and cortical spreading de-
polarization.6 Given this improved understanding of 
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underlying mechanisms, it is logical to conclude that 
efficacious future therapeutic strategies for reducing 
DCI and improving functional outcome in patients with 
SAH must elicit protection against not only large- artery 
vasospasm, but also other pathophysiological events 
including those disrupting the microcirculation. Given 
its well- described powerful and pleiotropic protective 
effects against ischemic brain injury shown by us7,8 
and others,9,10 we began studies to assess the bene-
fits of a therapeutic approach known as conditioning in 
experimental models of SAH.
Conditioning describes the phenomenon wherein 
endogenous injury resilience in brain and other 
tissues is augmented by exposure to a stressful, but 
sublethal, stimulus.11 A variety of conditioning agents 
and strategies have been examined in ischemic stroke 
and are found to enhance endothelial- dependent va-
sodilation,12 reduce blood– brain barrier breakdown13 
and vasogenic edema,14 and increase vascular pa-
tency,15 thereby supporting a vascular contribution 
to conditioning- induced protection. Given the cen-
tral role vascular deficits play in DCI pathophysiol-
ogy (large- artery vasospasm and microcirculatory 
deficits including microvessel thrombosis and auto-
regulatory dysfunction), the wide therapeutic window 
between SAH onset, and development of DCI, we 
have leveraged conditioning- based approaches to 
improve outcome after experimental SAH. In our 
initial proof- of- principle study, we showed that a 
brief period of hypoxia initiated before SAH (hy-
poxic preconditioning [HPreC]) markedly reduces 
large- artery vasospasm and improves neurological 
outcome, and that this protection is critically de-
pendent on endothelial NO synthase (eNOS).16 In a 
follow- up study also examining HPreC, we discov-
ered that SIRT1 (sirtuin 1) is an additional mediator 
of hypoxia- induced protection against vasospasm 
and neurological dysfunction.17 In the present 
study, we turned our attention toward translating 
these initial proof- of- principle discoveries to strat-
egies that can ultimately be applied to patients in 
the clinic (ie, a conditioning- based therapy initiated 
after aneurysmal SAH).
SIRT1 is a well- known nicotinamide adenine 
dinucleotide– dependent epigenetic modulator that 
regulates gene transcription and thereby impacts 
numerous functions including stress, inflamma-
tion, vessel function, and thrombosis.18 Although 
SIRT1 is known to have protective effects in cen-
tral nervous system diseases including Alzheimer’s, 
Parkinson’s,19 ischemic stroke,20 and traumatic brain 
injury,21 it has only recently been explored in the 
setting of SAH. Zhang and colleagues provided evi-
dence that SIRT1 plays a role in SAH- induced early 
brain injury (EBI).22 This finding has subsequently 
been validated in follow- up studies.23 Our laboratory 
showed SIRT1 is a key mediator of HPreC- induced 
protection against large- artery vasospasm and neu-
rological deficits after experimental SAH.17 Hence, 
we undertook the present study to build upon these 
initial findings and determine whether hypoxic con-
ditioning initiated after SAH (hypoxic postcondition-
ing [HPostC]) provides similarly robust protection 
against large- artery vasospasm and neurological 
deficits, whether it also provides protection at the 
level of microcirculatory deficits, and whether this 




• Hypoxic conditioning initiated after subarach-
noid hemorrhage (hypoxic postconditioning) 
provides robust protection against delayed cer-
ebral ischemia (DCI) including alleviating large- 
artery vasospasm, microvessel thrombosis, 
and sensory- motor neurological deficits.
• Genetic and pharmacologic inhibition of the 
nicotinamide adenine dinucleotide– dependent 
deacetylase, SIRT1 (sirtuin 1), blocks the DCI 
protection afforded by hypoxic postconditioning.
• Genetic overexpression of SIRT1 mimics the 
DCI protection afforded by hypoxic postcon-
ditioning in subarachnoid hemorrhage; post– 
subarachnoid hemorrhage administration of 
the SIRT1 activator, resveratrol, reduces DCI 
and improves neurological outcome in a SIRT1- 
mediated fashion.
What Are the Clinical Implications?
• Our results indicate that conditioning- based 
strategies, in particular SIRT1 activation, carry 
promise as a novel therapeutic approach to 
reducing DCI and improving neurological out-
come in patients suffering from a ruptured brain 
aneurysm.
Nonstandard Abbreviations and Acronyms
DCI delayed cerebral ischemia
EBI early brain injury
eNOS endothelial nitric oxide synthase
HPostC hypoxic postconditioning
HPreC hypoxic preconditioning
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METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request and approval of the appropriate institu-
tional review board.
Experimental Animals
All experimental procedures performed were ap-
proved by the Institutional Animal Care and Use 
Committee at Washington University and conformed 
to the National Institutes of Health Guidelines for the 
Care and Use of Animals in Research. We obtained 
12- to 14- week- old male C57BL/6J mice from Jackson 
Laboratories (Bar Harbor, ME). Whole body adult- 
inducible SIRT1- knockout and SIRT1- overexpressing 
mice were generated as described previously.24 In brief, 
mice with a targeted Sirt1 floxed mutant allele (B6;129- 
Sirt1tm1Ygu/J) were obtained from Jackson Laboratories 
and bred with mice expressing whole- body tamoxifen- 
inducible Cre (B6.129- Gt[ROSA]26Sortm1[cre/ERT2]
Tyj/J) obtained from Jackson Laboratories to generate 
tamoxifen- inducible whole- body SIRT1- knockout mice 
and wild- type littermate controls. Hemizygous con-
stitutive whole- body SIRT1- overexpressing mice (B6. 
CgTg[Sirt1]ASrn/J) and noncarriers on the same back-
ground were also obtained from Jackson Laboratories 
and bred to generate constitutive whole- body SIRT1- 
overexpressing mice (Sirt1- Tg) and littermate controls. 
All animals were acclimated under a 12- hour light/dark 
cycle controlled environment with free access to water 
and a standard mouse chow diet.
Experimental SAH Model
Experimental SAH was induced in mice by the endovas-
cular perforation technique as described in our earlier 
publications.16,25,26 Briefly, mice were anesthetized with 
isoflurane (2% induction, 1.5% maintenance) in room 
air with core body temperature maintained at 37 °C 
by a thermo- regulated heating pad. A midline incision 
made in the neck and the external carotid artery was 
exposed. A 5- 0 nylon suture was introduced into the 
external carotid artery and advanced distally through 
the internal carotid artery until reaching the internal ca-
rotid artery bifurcation. The suture was then advanced 
further to induce SAH. The suture was removed, and 
the external carotid artery was ligated. Mice were al-
lowed to recover from anesthesia in an incubator and 
then returned to their cages. Mice undergoing sham 
surgery underwent the same procedure except for su-
ture perforation of the internal carotid artery.
Neurological deficits were assessed daily until the 
time the animal was euthanized, and DCI- related pa-
thology (vasospasm and microvessel thrombus) was 
assessed on post- SAH day 2. This time point was 
chosen based on the established time course of DCI- 
related pathology in the endovascular perforation 
mouse model of SAH, a time course that is consider-
ably faster than that seen in humans (for review, see 
LeClerc et al27). To evaluate distribution of blood along 
subarachnoid vessels, mice were transcardially per-
fused with heparinized PBS, and the brain was carefully 
removed. In sham- operated animals, there is no visible 
blood, whereas after SAH, extravasated blood consis-
tently covers the middle cerebral artery (MCA) and is 
distributed along the larger arteries that branch from the 
MCA (Figure S1). Animals that died during or soon after 
the surgical procedure, those from the SAH group with 
absence of subarachnoid blood, those from the sham 
group with presence of subarachnoid blood, and those 
with the presence of dense hemiparesis within 6 hours 
of surgery (indicative of inadvertent MCA occlusion) 
were excluded. Otherwise, all SAH and sham- operated 
animals that survived and were able to complete neu-
robehavioral assessment were included in our findings.
Hypoxic Postconditioning
Figure  S1 demonstrates the schematic representa-
tion of our experimental design and protocols. In the 
initial dose- finding experiment (Figure S2), mice were 
placed in a hypoxic chamber 3 hours after SAH and 
exposed to air containing 8% O2/92% N2 for 2 hours 
or 11% O2/89% N2 for 1 hour with access to food and 
water ad libitum; animals were then returned to their 
cages. For subsequent experiments, exposure to air 
containing 8% O2/92% N2  for 2  hours was used as 
the conditioning stimulus and administered beginning 
3 hours after SAH. This stimulus was repeated daily at 
roughly 24- hour intervals following SAH until the day 
the animal was euthanized. Normoxic controls were 
placed in chambers containing room air.
SIRT1 Deacetylase Activity
SIRT1 deacetylase activity in the cerebral cortex 
was determined using an SIRT1 Activity Assay Kit 
(ab156065; Abcam, Cambridge, MA). In brief, fluoro- 
substrate peptide, fluoro- deacetylated peptide, and 
nicotinamide adenine dinucleotide were successively 
added to the SIRT1 assay buffer followed by incubation 
with the tissue sample, as well as the developer buffer 
and recombinant SIRT1 (5 mg) at 37 °C for 60 minutes. 
After excitation at 340 nm, emitted light was detected 
at 440 nm using a microtiter plate fluorometer. The flu-
orescence intensity of the assay buffer was subtracted 
from each experimental sample.
Drug Administration
A selective SIRT1 inhibitor EX- 527 (10  mg/kg; Tocris 
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in β- cyclodextrin:PBS) was administered to mice via in-
traperitoneal injection beginning 2 hours after surgery 
and 1 hour before HPostC and continued once daily 
thereafter. Resveratrol (6  mg/kg IP, BID; Sigma, St. 
Louis, MO) or vehicle (7.5% dimethylsulfoxide in corn 
oil) was administered starting 3  hours after SAH or 
sham surgery and repeated every 12 hours until the 
morning of post- SAH day 2. Vehicle- treated animals 
were administered equal volumes of dimethylsulfox-
ide. We (Figure S3) and others have shown that both 
EX- 527 and resveratrol are potent regulators of SIRT1 
deacetylase activity.28 A whole- body Cre- inducible 
SIRT1- knockout mouse was generated by intraperito-
neal administration of tamoxifen (75 mg/kg) for 5 con-
secutive days and subjected to SAH 9 to 10 days after 
the last injection. The resultant deletion of the catalytic 
region of SIRT1 in SIRT1- knockout mice was evaluated 
1 week after the last tamoxifen injection by protein ex-
pression analysis.
Cerebral Vasospasm Assessment
Vasospasm was assessed in the ipsilateral MCA on 
postsurgery day 2 via cerebrovascular casting, as 
previously described.16,25,26,29 Briefly, mice were anes-
thetized with isoflurane and transcardially perfused at 
a constant pressure of 80±5  mm  Hg with 15  mL of 
10  mmol/L glucose PBS– heparin (1000 USP U/mL), 
followed by 20 mL of 4% paraformaldehyde and 20 mL 
of the 20  μmol/L 5- (and- 6)- carboxy- X- rhodamine, 
succinimidyl ester (5(6)- ROX, SE) working solution. A 
10- mmol/L stock solution of 5(6)- ROX, SE (AS- 81113; 
AnaSpec, Freemont, CA) in dimethylsulfoxide was di-
luted into 10  mmol/L glucose– PBS for a final work-
ing solution of 20 μmol/L 5(6)- ROX, SE in 10 mmol/L 
glucose– PBS. After perfusion fixation, brains were 
extracted under a dissecting microscope (SMZ 800; 
Nikon) and stored in 4% paraformaldehyde at 4 °C for 
48 hours and then transferred into a 30% sucrose so-
lution. Blood vessels imaged using a charge- coupled 
device (CCD) camera (CoolSNAP 3s; Roper Scientific, 
Tucson, AZ). Spasm of the ipsilateral proximal MCA 
was assessed by recording 3 independent measure-
ments of the smallest lumen diameter within the first 
1000 μm of the MCA outside the lateral sulcus. All vas-
cular measurements were performed by a single ob-
server blinded to experimental groups.
Microvessel Thrombus 
Immunohistochemistry
The extent of microvessel thrombi formation was as-
sessed by immunohistochemistry in a blinded fash-
ion by an independent investigator for the presence 
of fibrinogen deposition, as previously described,26 
on post- SAH day 2. Briefly, mice were transcardially 
perfused with heparinized PBS, brains were then 
extracted and fixed in 4% paraformaldehyde for 
48  hours, and 50- μm thick, free floating, coronal 
brain sections were then blocked in PBS containing 
1% bovine serum albumin, 0.2% dry milk, and 0.1% 
Triton- X100 for 1 hour, followed by overnight incuba-
tion at 4 °C with with rabbit anti- fibrinogen antibody 
(1:1000 dilution; Abcam). The free- floating sections 
were then incubated with biotinylated goat- anti rabbit 
antibody (Bio- Rad, Hercules, CA) at room temperature 
for 2 hours, followed by incubation with VECTASTAIN 
Elite ABC Kit solution (Vector Laboratories, 
Burlingame, CA), and 3,3′- diaminobenzidine tetra-
chloride solution. Stained sections of the left cerebral 
cortex were imaged using a Nikon E- 600ME micro-
scope. Microvessel thrombi formation was quantified 
by measuring at 20× magnification, and the percent 
coverage of fibrinogen- immunoreactive areas of pari-
etal cortex (4– 5 sections per brain) ipsilateral to SAH 
injury was determined using the threshold function 
in ImageJ software (National Institutes of Health, 
Bethesda, MD).
Neurological Deficit Testing
Neurobehavioral outcome in mice was examined daily 
using our Neuroscore test, as previously described.26 
Briefly, neurological function was graded based on the 
combination of a motor score (0– 12) that evaluated 
spontaneous activity, symmetry of limb movements, 
climbing, balance and coordination, and a sensory 
score (4– 12) that evaluated body proprioception and 
vibrissae, visual, and tactile responses.
Western Immunoblotting
All the extraction operations were performed on 
ice. Briefly, the tissues of the cerebral cortex were 
purified using radioimmunoprecipitation assay lysis 
buffer. Protein concentration was quantified by 
bicinchoninic protein assay kit (DC protein assay kit; 
Bio- Rad). The equivalent extracted protein lysates 
(40– 60 µg) were diluted with 2× Laemmli buffer, de-
natured for 5 minutes at 95 °C, loaded onto sodium 
dodecyl sulphate polyacrylamide gels, and blotted 
as previously described.30 After transferring onto 
immobilon- P/polyvinylidene difluoride membranes 
(Millipore, Billerica, MA), the membranes were 
blocked in TBST buffer (0.05 M Tris pH 7.4, 0.15 M 
NaCl, 0.05% Tween 20) containing 5% (w/v) albumin 
(Sigma) at room temperature for 1 hour. Subsequently, 
membranes were incubated at 4 °C overnight with 
the following primary antibodies, which were dis-
solved in 5% albumin in TBST solution: mouse anti- 
mouse SIRT1 (Abcam) and anti- α tubulin antibody 
(ab18251; rabbit 1:3000). Blots were developed 
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immunoglobulin G secondary antibody for 1 hour at 
room temperature. The relative expression of protein 
bands was visualized using the GeneSys Software 
(Alpha Metrix Biotec, Rödermark, Germany) with the 
enhanced chemiluminescence substrate (Millipore). 
Densitometric quantification of the bands was per-
formed using Image J software.
Statistical Analysis
We estimated sample sizes using effect sizes based 
on our previous publications as well as pilot experi-
ments, using a significance level of 0.05 and a power 
of 0.80. Therefore, our studies were appropriately 
powered for each end point to obtain statistical sig-
nificance. Following testing for the homoscedastic-
ity and the normal distribution by Shapiro- Wilk test, 
1- way ANOVA followed by Tukey multiple compari-
sons post hoc tests were performed for vasospasm 
and microvessel thrombosis. Neuroscore data were 
analyzed using repeated- measures ANOVA followed 
by Tukey post hoc test for multiple comparisons. 
Nonparametric data with 2 groups were analyzed 
using the Mann- Whitney U test. Data are presented 
as mean with SD. P<0.05 was considered as statisti-
cally significant.
RESULTS
HPostC Attenuates SAH- Induced 
Vasospasm, Microvessel Thrombosis, and 
Neurological Deficits
First, we assessed whether HPostC provides macro- 
and microvascular protection. Mice were subjected to 
SAH and then exposed 3 hours later to an episode of 
severe hypoxia (8% O2 for 4 hours) with the intention 
of evaluating large- artery vasospasm and neurologi-
cal deficits for protective effects; however, mortality 
with this severe dose of HPostC was ≈60% (data not 
shown). We then subjected mice that underwent SAH 
to mild (11% O2 for 1  hour) or moderate (8% O2 for 
2  hours) hypoxia, both initiated 3  hours after SAH, 
and then repeated daily until the animal was eutha-
nized. Both doses were well tolerated in control and 
SAH mice, with mortality rates of 2% and 10%, re-
spectively. Although mild HPostC produced no signifi-
cant neurovascular protection, moderate HPostC led 
to a significant reduction in large- artery vasospasm, 
improved neurological deficits, and provided marked 
protection against SAH- induced cortical microvessel 
thrombosis compared with untreated control mice 
(Figure S2). Given the robust neurovascular protection 
provided by moderate HPostC initiated 3 hours after 
SAH, this treatment paradigm was used for all subse-
quent experiments.
HPostC Increases SIRT1 Enzymatic 
Activity
Because SIRT1 is upregulated by hypoxia31 and is a 
known regulator of eNOS,32 we hypothesized that 
SIRT1 directly participates in HPostC- induced protec-
tion against SAH. To examine this hypothesis, we as-
sessed the impact of HPostC on SIRT1 deacetylase 
activity and protein expression in mice subjected to 
SAH. We found that SIRT1 activity, but not protein ex-
pression levels (data not shown), was significantly up-
regulated by HPostC in SAH group, remaining elevated 
for 48 hours after SAH (Figure 1A). In contrast, SIRT1 
activity in nonpostconditioned mice was only signifi-
cantly elevated at 12 hours after SAH, perhaps reflect-
ing an endogenous response to help protect the brain 
(Figure 1B).
SIRT1 Contributes to the DCI Protection 
Afforded by HPostC: Validation by 
Pharmacologic and Genetic Inhibition
We next used a pharmacologic and genetic approach 
to obtain causal evidence for the involvement of SIRT1 
in HPostC- induced DCI protection. One cohort of mice 
was treated with the SIRT1- specific pharmacologic in-
hibitor, EX527, before HPostC. We found that the strong 
protection against DCI- associated large- artery vasos-
pasm (Figure 2A), microvessel thrombosis (Figure 2B), 
and neurological deficits (Figure  2C) afforded by 
HPostC was blocked by EX527. We also examined the 
role of SIRT1 in HPostC- induced DCI protection using 
tamoxifen- inducible global SIRT1- knockout (Sirt1−/−) 
mice of either sex, the latter of which we showed by 
immunoblotting to exhibit an absence of SIRT1 pro-
tein in the brain (Figure 3A). As with the pharmacologic 
study, the robust protection against large- artery vasos-
pasm (Figure 3B), microvessel thrombosis (Figure 3C), 
and neurological deficits (Figure  3D) in Sirt1+/+ mice 
was lost in their littermate Sirt1−/− mice. Taken together, 
these pharmacologic and genetic studies indicate 
HPostC- induced protection against SAH- induced DCI 
and accompanying neurological deficits is critically de-
pendent on SIRT1.
SIRT1 Contributes to the DCI Protection 
Afforded by HPostC: Validation by 
Pharmacologic and Genetic Potentiation
Additional genetic and pharmacologic studies were 
undertaken to support SIRT1 as a mediator of DCI 
protection. Constitutive global SIRT1- overexpressing 
mice of either sex were used to assess the efficacy of 
SIRT1 augmentation as a strategy to attenuate SAH- 
induced DCI and neurological deficits. We found a 




 http://ahajournals.org by on D
ecem
ber 14, 2021
J Am Heart Assoc. 2021;10:e021113. DOI: 10.1161/JAHA.121.021113 6
Diwan et al SAH Protection by SIRT1 Activation
vasospasm (Figure  4A), microvessel thrombosis 
(Figure  4B), and neurological deficits (Figure  4C) in 
SIRT1- transgenic mice (Sirt1- Tg), compared with wild- 
type littermate controls, in the absence of HPostC. 
Notably, the degree of neurovascular protection in 
SIRT1- transgenic mice was comparable to that seen 
in wild- type mice treated with HPostC. We then as-
sessed the ability of the SIRT1 activator resveratrol to 
pharmacologically mimic the DCI- protective effects 
of HPostC. Resveratrol, administered 3  hours after 
Figure 1. SIRT1 (sirtuin 1) deacetylase activity after subarachnoid hemorrhage (SAH) and hypoxic 
postconditioning (HPostC).
SIRT1 deacetylase activity in brain lysates was quantified 6 to 48 hours after SAH plus HPostC (A) and 
6 to 48 hours after SAH or sham surgery (B) (n=5 per group). *P<0.05 vs sham and n.s. P>0.05 by 1- 
way ANOVA with Tukey multiple comparisons test. Data represent the mean with SD. n.s. indicates not 
significant.
Figure 2. Hypoxic postconditioning (HPostC)- induced delayed cerebral ischemia protection against subarachnoid 
hemorrhage (SAH) is lost following pharmacological inhibition of SIRT1 (sirtuin 1).
HPostC- induced protection against vasospasm (A), microvascular thrombi (B), and neurological deficits (C) induced by SAH is 
abrogated by the SIRT1 inhibitor EX527. Mice were subjected to SAH or sham surgery followed 2 hours later by treatment with the 
SIRT1 inhibitor, EX527 (10 mg/kg, IP) or vehicle (Veh), and then underwent HPostC (8% O2×2 hours, repeated daily) or normoxia 
(Norm; room air×2 hours, repeated daily) starting at 3 hours after SAH/sham surgery. A, Vasospasm in the left middle cerebral artery 
was assessed on postsurgery day 2 (n=12– 17 mice). *P<0.05 and n.s. P>0.05 by 1- way ANOVA with Tukey multiple comparisons 
test. B, Cortical microthrombosis was quantified as the percent of fibrinogen- positive microvessels in the ipsilateral parietal cortex 
microcirculation (n=9). *P<0.05 and n.s. P>0.05 by 1- way ANOVA with Tukey multiple comparisons test. C, Neuroscore was assessed 
on days 0 to 2 (n=12– 17 mice). *P<0.05 and #P<0.05 vs Normoxia:Sham:Veh and HPostC:SAH:Veh. Statistical significance was analyzed 
by repeated- measures ANOVA followed by Tukey multiple comparisons test. Data represent the mean with SD. Excluded=1 mouse 
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SAH in mice, significantly attenuated large- artery 
vasospasm (Figure  5A), microvessel thrombosis 
(Figure 5B), and neurological deficits (Figure 5C) as 
compared with vehicle- treated control mice. Given 
that resveratrol not only activates SIRT1 but also 
has antioxidant and neuroprotective properties,33 we 
sought to verify that the resveratrol- induced DCI pro-
tection was SIRT1 mediated by cotreating a subgroup 
of mice with the SIRT1 inhibitor, EX527. We found 
that the DCI protection afforded by resveratrol was 
lost in EX527- treated mice (Figure  5A through 5C). 
Moreover, we demonstrated that resveratrol- induced 
increases in cerebral SIRT1 activity in mice with SAH 
were abrogated by EX527 treatment (Figure S3), also 
supporting our contention that resveratrol- mediated 
DCI protection was largely the result of increased 
SIRT1 activity secondary to resveratrol administra-
tion. Taken together, these results indicate that res-
veratrol provides robust SIRT1- mediated protection 
against DCI and neurological deficits.
DISCUSSION
In the present study, several important insights were 
advanced: (1) Hypoxic conditioning initiated at a thera-
peutically relevant time (3  hours) after SAH (HPostC) 
provides robust protection against large- artery vasos-
pasm and neurological deficits. (2) HPostC not only 
protects against macrovessel dysfunction, but also 
protects at the level of the microcirculation by reducing 
thrombosis. (3) Multifaceted HPostC- induced DCI pro-
tection is critically dependent on SIRT1, given that our 
neurovascular protection metrics were lost in SIRT1- 
null mice as well as in EX527- treated mice. (4) Genetic 
overexpression of SIRT1 mimics the DCI protection af-
forded by HPostC. (5) Administration of the SIRT1 ac-
tivator, resveratrol, provides strong protection against 
DCI and improves neurological outcome in an SIRT1- 
dependent manner. Collectively, our findings demon-
strate that conditioning strategies designed to activate 
powerful endogenous protective mechanisms can 
Figure 3. Hypoxic postconditioning (HPostC)- induced protection against subarachnoid hemorrhage (SAH) is lost in 
inducible SIRT1 (sirtuin 1)- null mice.
HPostC- induced protection against SAH- induced vasospasm (B), microvascular thrombi (C), and neurological deficits (D) seen in 
wild- type (Sirt1+/+) mice is lost in tamoxifen- induced SIRT1- null (Sirt1−/−) littermates. Sirt1+/+ and Sirt1−/− mice were subjected to SAH 
or sham surgery, and then underwent HPostC (8% O2×2 hours, repeated daily) or normoxia (Norm; room air×2 hours, repeated daily) 
beginning 3 hours after surgery. A, Representative immunoblot for SIRT1 in brain cortex of 2 wild- type (Sirt1+/+) and 2 SIRT1- null 
(Sirt1−/−) mice, with β- tubulin as a loading control. B, Vasospasm in the left middle cerebral artery was assessed on postsurgery 
day 2 (n=7– 12). *P<0.05 and n.s. P>0.05 by 1- way ANOVA with Tukey multiple comparisons test. C, Cortical microthrombosis, 
quantified as the percent of fibrinogen- positive microvessels in the ipsilateral parietal cortex microcirculation (n=8– 10). *P<0.05 and 
n.s. P>0.05 by 1- way ANOVA with Tukey multiple comparisons test. D, Neuroscore was assessed on days 0 to 2 (n=7– 12). *P<0.05 vs 
Sirt1+/+:Sham:Norm and Sirt1+/+:SAH:HPostC. #P<0.05 and &P<0.05 vs Sirt1−/−:Sham:Norm. Statistical significance was analyzed by 
repeated- measures ANOVA followed by Tukey multiple comparisons test. Data represent the mean with SD. Excluded=1 mouse from 
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provide strong neurovascular protection even when 
initiated after induction of SAH. As such, we contend 
that postconditioning with SIRT1- promoting therapeu-
tics represents a clinically viable treatment strategy for 
reducing secondary brain injury and improving overall 
outcome in patients presenting with SAH.
In recent years, we and others have documented that 
a variety of conditioning agents including hypoxia15,16   
Figure 4. Constitutive overexpression of SIRT1 (sirtuin1) provides strong protection against subarachnoid hemorrhage 
(SAH).
Extent of SAH- induced vasospasm (A), microvascular thrombosis (B), and neurological deficits (C) are all significantly reduced in 
constitutive SIRT1- overexpressing (Sirt1- Tg) relative to wild- type (WT) littermate controls. WT and Sirt1- Tg mice underwent sham 
or SAH surgery. A, Vasospasm in the left middle cerebral artery was assessed on day 2 (n=11– 20). *P<0.05 and n.s. P>0.05 by 1- 
way ANOVA with Tukey multiple comparisons test. B, Cortical microthrombosis was quantified as the percent of fibrinogen- positive 
microvessels in the ipsilateral parietal cortex microcirculation (n=8– 13).; *P<0.05 by 1- way ANOVA with Tukey multiple comparisons 
test. C, Neuroscore was assessed on days 0 to 2 (n=11– 20). *P<0.05 vs Sham:WT. #P<0.05 vs SAH:WT. Statistical significance was 
analyzed by repeated- measures ANOVA followed by Tukey multiple comparisons test. Data represent the mean with SD. Excluded=1 
mouse from SAH:WT and SAH:Sirt1- Tg groups. n.s. indicates not significant.
Figure 5. SIRT1 (Sirtuin 1) activation by post- subarachnoid hemorrhage (SAH) resveratrol (RSV) provides strong protection 
against SAH.
Extent of SAH- induced vasospasm (A), microvascular thrombus (B), and neurological deficits (C) are all significantly reduced by RSV 
treatment initiated 3 hours after SAH. Administration of the SIRT1 inhibitor EX527 concomitant with RSV abrogates the protective 
effect of RSV on SAH- induced vasospasm (A), microvascular thrombosis (B), and neurological deficits (C). Wild- type mice underwent 
sham or SAH surgery and were treated with RSV or RSV+EX527 starting 2 hours after SAH. (A) Vasospasm in the left middle cerebral 
artery was assessed on postsurgery day 2 (n=11– 12). *P<0.05 and n.s. P>0.05 by 1- way ANOVA with Tukey multiple comparisons 
test. B, Cortical microvessel thrombosis was quantified as the percent of fibrinogen- positive microvessels in the ipsilateral parietal 
cortex microcirculation (n=7– 10). *P<0.05 and n.s. P>0.05 by 1- way ANOVA with Tukey multiple comparisons test. C, Neuroscore was 
assessed on days 0 to 2 (n=11– 12). *P<0.05. #P<0.05 vs Sham:Veh and SAH:RSV. Statistical significance was analyzed by repeated- 
measures ANOVA followed by Tukey multiple comparisons test. Data represent the mean with SD. Excluded=1 mouse from SAH:Veh., 
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anesthetics34 and lipopolysaccharide35 provide power-
ful protection in the setting of brain ischemia and have 
also shown evidence that conditioning approaches 
such as anesthetics and remote limb ischemia may sim-
ilarly mitigate SAH- induced neurovascular dysfunction 
in patients.34 Although the suitability of conditioning- 
based therapy for SAH had been proposed for 
years,9,36 the first application of a conditioning- based 
strategy to SAH came from our group in 2011,16 in 
which we demonstrated that a one- time exposure to 
hypoxia before the induction of SAH provides robust 
protection against subsequent large- artery vasospasm 
and neurological deficits. We also provided mechanis-
tic evidence that this DCI protection involved eNOS- 
derived NO, a molecule critically involved in endothelial 
cell and cerebral vessel physiology, strongly implicated 
in vasospasm pathophysiology and regulated by mul-
tiple mechanisms at transcriptional and posttransla-
tional levels.37 One well- described regulator of eNOS 
is SIRT1, which is hypoxia responsive and important 
in regulating endothelium- dependent, eNOS- mediated 
vascular homeostasis.38 Given this regulatory connec-
tion between eNOS and SIRT1, we recently extended 
findings in our 2011 study to show that SIRT1 is likely 
involved in HPreC protection against SAH- induced 
macro- and microvascular injury.17 In the present study, 
we extend these proof- of- principle findings in 3 key 
ways: (1) We show hypoxic conditioning initiated after 
SAH (HPostC) produces DCI protection at a magni-
tude similar to HPreC17. (2) We demonstrate that DCI 
protection occurs not only by attenuating vasospasm 
in large cerebral arteries, but also reduces the extent 
of SAH- induced thrombosis in the microcirculation. (3) 
We provide cross- validating genetic and pharmaco-
logic evidence that SIRT1 contributes significantly to 
HPostC- induced DCI protection. These findings sup-
port postconditioning with SIRT1- activating agents as 
a novel, clinically viable therapeutic approach to atten-
uating SAH- induced secondary brain injury.
Importantly, SIRT1 has previously been explored as 
a therapeutic target for another important, although 
less common, pathophysiological event following 
SAH, EBI. This form of secondary brain injury involves 
a complex set of pathological processes including 
blood– brain barrier disruption, neuroinflammation, 
neuronal apoptosis, and cerebral edema.39 Studies 
have demonstrated that administering resveratrol soon 
after40,41 experimental SAH provides significant protec-
tion against a variety of histologic markers of EBI as 
well as early neurological deficits (24 hours after SAH). 
More direct evidence supporting the possibility that 
SIRT1 mediates EBI- protective effects was provided by 
Zhang and colleagues, showing that a SIRT1 activator 
(activator 3) reduces and inhibitor (sirtinol) exacerbates 
EBI in the rat prechiasmatic cistern model of SAH.22 
Taken together with our pharmacologic and genetic 
studies reported herein implicating SIRT1 in mediating 
powerful protection against the more common and 
more morbid condition of DCI, a promising therapeu-
tic approach for SAH emerges. Moreover, as opposed 
to the majority of therapeutic approaches designed to 
target one pathophysiological process in SAH- induced 
brain injury (eg, large- artery vasospasm), hypoxic 
conditioning, and more specifically SIRT1- directed 
therapies, have the benefit of targeting multiple patho-
physiological processes implicated in poor outcomes 
after SAH (eg, EBI and DCI, macro- and microvessel 
dysfunction, and neuronal cell death).
There are several limitations to our study. First, al-
though we provide evidence indicating hypoxia and 
resveratrol increase SIRT1 activity in a temporally rel-
evant fashion, the mechanisms by which this occurs 
were not explored. Second, although we rigorously 
examined 2 key components of SAH- induced DCI (ie, 
large- artery vasospasm and microvessel thrombosis), 
other contributors were not assessed including auto-
regulatory dysfunction and cortical spreading depres-
sion. Third, we did not perform long- term assessment 
of SAH- induced neurobehavioral deficits, which will be 
important to pursue given the morbidity associated 
with SAH- induced cognitive dysfunction in patients. 
Fourth, we were unable to test SIRT1 activators with 
higher potency and specificity given that these agents 
are largely proprietary and unavailable. Fifth, we recog-
nize that it is possible that the protective effect of SIRT1 
activation on DCI may have resulted, at least in part, 
from a beneficial impact on EBI, because some have 
suggested a causal connection between onset of EBI 
and subsequent development of DCI.22,42,43
In summary, results from the present study indicate 
that HPostC elicits a powerful protective response 
against DCI, that this protection is multifaceted, act-
ing at both macro- and microvascular levels, and that 
SIRT1 is a critical downstream inducer of these DCI- 
protective actions. Thus, SIRT1- directed pharmaco-
logic strategies implemented after SAH carry great 
promise for combating SAH- induced DCI and improv-
ing patient outcomes. Additional studies are warranted 
to further elucidate the molecular cascade leading to 
HPostC- induced DCI protection, to determine whether 
HPostC also provides significant protection against EBI 
and if so whether this is also SIRT1 mediated, and to 
explore the therapeutic potential of novel approaches 
for augmenting and/or activating SIRT1 in patients pre-
senting with SAH.
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Red and black arrows indicate time points for surgical procedures (sham or SAH surgery), hypoxic 
postconditioning (HPostC) treatments, and assessment of vasospasm, microvessel thrombi (MVT), 
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Figure S2. Hypoxic Postconditioning (HPostC) protects against SAH-induced vasospasm, 




Mice underwent SAH or sham surgery followed 3 h later by HPostC (8% O2 for 2h, or 11% O2 for 
1h) or Normoxia (Norm; room air x 2 h, repeated daily). HPostC was then repeated daily until 
animal sacrifice. (A) Vasospasm was assessed in the left middle cerebral artery (MCA) on Day 3; 
*p<0.05, n.s. p>0.05 by one-way ANOVA with Tukey multiple comparisons test. (B) Neuroscore 
was assessed daily until animal sacrifice; *p<0.05 vs. Sham:Norm; #p<0.05 vs. SAH:Normoxia 
by repeated-measures ANOVA followed by Tukey’s multiple comparisons test. (C) Cortical 
microthrombosis was determined as percent coverage of ipsilateral parietal cortex; *p<0.05 by 
one-way ANOVA with Tukey multiple comparisons test. Data represent the mean with SD. n.s. 
indicates not significant. Representative images of mice that underwent (D) Sham and (E) SAH 
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Figure S3. Effects of treatment with either resveratrol (RSV) or resveratrol + EX527 on 
Sirtuin 1 (SIRT1) enzymatic activity. 
 
 
Wild-type mice underwent sham or SAH surgery and were treated with resveratrol or resveratrol 
plus the SIRT1 inhibitor EX527 starting 2 h after SAH and continued daily until animal sacrifice. 
SIRT1 deacetylase activity in brain lysates was quantified 48 h after surgery. (n=5-7) *p<0.05 vs 
Sham and n.s. p>0.05 by one-way ANOVA with Tukey multiple comparisons test. Data represents 
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